PHARMA HOLDINGS AS

ACTIVE

Utländsk Adr - Foreign Addr, Norwaywww.pharmaholdings.noPrivate

Clinical Trials

3 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

57.1%

Phase 1

42.9%

Trial Status Distribution

Active, not recruiting

14.3%

Completed

42.9%

Not yet recruiting

28.6%

Unknown

14.3%

Clinical Trials

Trials sponsored by this organization (7)

Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus

Phase 2

Completed

interventional

Sep 202227 participants

Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection

Phase 2

Not yet recruiting

interventional

Feb 202260 participants

Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.

Phase 2

Unknown

interventional

May 202160 participants

LTX-109 as Treatment for Hidradenitis Suppurativa

Phase 1

Completed

interventional

Mar 202111 participants

A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus

Phase 1

Completed

interventional

Feb 202115 participants

A double-blind, placebo-controlled, interventional parallel group study to evaluate the antiviral effect of a single nasal application of LTX-109 3% gel, in comparison to placebo gel, in subjects with COVID-19 infectio

Phase 1

Active, not recruiting

Feb 202160 participants

Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infectio

Phase 2

Not yet recruiting

interventional

Approvals

No approval data available

News

No news articles found

Back to Organizations